Navigation Links
Kensey Nash Corporation Adopts Cash Dividend Policy; Declares Initial Quarterly Dividend of $0.25 per Share
Date:1/3/2012

s part of our ongoing efforts to maximize stockholder value and related return on investment for our stockholders.  Since 2008, we have repurchased approximately $115 million of our common stock."

About Kensey Nash Corporation. Kensey Nash Corporation is a medical device company primarily focused on regenerative medicine utilizing its proprietary collagen and synthetic polymer technology. The Company is recognized as a leader for innovative product development and unique technology in the field of resorbable biomaterials. The Company has an extensive range of products, which are sold through strategic partners in multiple medical markets, including the cardiology, orthopaedic, sports medicine, spine, endovascular and general surgery markets. For more information, visit www.kenseynash.com.

Cautionary Note for Forward-Looking Statements. This press release contains forward-looking statements that reflect the Company's current expectations about its prospects and opportunities and are covered by the "Safe Harbor for Forward-Looking Statements" provided by the Private Securities Litigation Reform Act of 1995. The Company has tried to identify the forward-looking-statements by using words such as "plan," "expect," "will," "would," "should," "believe," "guidance" and similar expressions, but these words are not the exclusive means for identifying such statements. The Company's expectation that dividends will be paid on a quarterly basis assumes that the Company's financial condition will permit payment under Delaware law, that the Company will generate sufficient cash flow to warrant the payment of a dividend, and that the declaration and payment of cash dividends can be made in accordance with applicable law and agreements of the Company.  The Company also cautions that a number of other risks, uncertainties and other important factors could cause the Company's actual results to differ materia
'/>"/>

SOURCE Kensey Nash Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Kensey Nash to Enter Into Mediation with St. Jude Medical over Angio-Seal Contract Disputes
2. Kensey Nash Corporation Receives $1.9m NIH Grant for Tendon Product Research
3. Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2012 Earnings Release Date and Teleconference
4. Kensey Nash Investor to Present at the Jefferies Global Healthcare Conference in London
5. Kensey Nash Investor Conference Schedule
6. Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results
7. Kensey Nash Corporation Announces Its Fourth Quarter and Fiscal Year End 2011 Earnings Release Date and Teleconference
8. Kensey Nash Announces New Unsecured Revolving Credit Facility
9. Kensey Nash to Present at the Jefferies 2011 Global Healthcare Conference
10. Kensey Nash Corporation Announces Its Third Quarter Fiscal Year 2011 Earnings Release Date and Teleconference
11. Kensey Nash to Present at the Canaccord Genuity Musculoskeletal Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... , Nov. 18, 2014  NxStage ® ... leading manufacturer of innovative dialysis products , ... Express dialyzer for the in-center, hemodialysis market. ... which is designed to reduce the amount of ... the number of touch point contamination sites.  The ...
(Date:11/18/2014)... N.J. , Nov. 18, 2014 ... 230,000 American women this year who get a ... today announced new resources for case managers to ... and 5—to navigate the myriad physical, emotional and ... resources are available at no cost via the ...
(Date:11/18/2014)... , Nov. 18, 2014  TransCelerate BioPharma ... most recent manuscript on Risk-Based Monitoring (RBM), ... Quality Control Measure in Clinical Trials ," ... Innovation & Regulatory Science  (TIRS) journal. Developed ... with Medidata, the manuscript examines the value ...
Breaking Medicine Technology:NxStage Launches New Streamline Express Dialyzer With Pre-attached Blood Tubing Set 2New Breast Cancer Resources: Commission For Case Manager Certification Adds Specialty Tools to Case Management Body of Knowledge Online Learning Center 2TransCelerate BioPharma Inc. Publishes Recommendation on Use of Source Data Verification in Risk-Based Monitoring, Releases Third Update on Initiative Progress 2TransCelerate BioPharma Inc. Publishes Recommendation on Use of Source Data Verification in Risk-Based Monitoring, Releases Third Update on Initiative Progress 3
... - Ambrilia,Biopharma Inc. (TSX:AMB), a biopharmaceutical company developing,novel ... and,cancer, held its Annual General and Special Meeting ... novel series of HIV,integrase inhibitors and recent developments ... Chairman of the Board, Mr. Frederic,Porte, and a ...
... 2007 /PRNewswire/ -- Results of the,Option (TOcilizumab ... first multinational Phase III study outside,of Japan, ... 4mg/kg,or 8mg/kg) plus methotrexate achieved a significant ... symptoms of moderate to,severe rheumatoid arthritis (RA) ...
Cached Medicine Technology:Ambrilia Highlights Encouraging Data for its HIV Integrase,Inhibitor Program and Recent Developments at Annual Meeting 2Ambrilia Highlights Encouraging Data for its HIV Integrase,Inhibitor Program and Recent Developments at Annual Meeting 3Ambrilia Highlights Encouraging Data for its HIV Integrase,Inhibitor Program and Recent Developments at Annual Meeting 4Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 2Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 3Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 4Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 5
(Date:11/21/2014)... First Choice Emergency Room ... new facility is located at 225 E. Parkwood Drive, ... are pleased to join the Friendswood community and look ... here,” said Dr. Siddiqi, Facility Medical Director of First ... the opening, First Choice Emergency Room made a donation ...
(Date:11/21/2014)... (PRWEB) November 21, 2014 M3 Global ... verified healthcare professional panel, today announced two important leadership changes ... Roni DasGupta as President of Market Research, Americas and the ... Europe. , Ms. DasGupta joined M3 in 2011 ... most recently Head of Sales. Roni has over 17 ...
(Date:11/21/2014)... By Dennis Thompson ... -- Overweight or obese women who get pregnant are much ... disease as an adult, new research suggests. But it ... in that trend, the researchers added. "Mothers who are ... study author Dr. Michael Mendelson. He is a research fellow ...
(Date:11/21/2014)... 20, 2014 (HealthDay News) -- Some people with cochlear ... internal magnet when they undergo an MRI scan, a ... by the researchers, about 300,000 people worldwide have cochlear ... people who are deaf or have severe hearing loss. ... with cochlear implants when undergoing MRI. One expert ...
(Date:11/21/2014)... By Serena Gordon ... -- Two U.S. government agencies have proposed new rules ... a clinical trial was successful or not. The ... required to publish summaries of their results to ClinicalTrials.gov -- ... of Health (NIH) and the U.S. Department of Health and ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Opens New Facility in Friendswood, Texas 2Health News:M3 Global Research Announces Leadership Team Promotions in US and EU 2Health News:Kids Born to Overweight Moms May Face Higher Heart Risks as Adults 2Health News:MRI Can Be Painful, Disruptive for People With Cochlear Implants 2Health News:U.S. Proposes Greater Public Access to Data From Clinical Trials 2
... researchers identify a molecular mechanism underlying a,genetic ... Aug. 11 St. Jude Children,s,Research Hospital ... underlying the genetic brain malformation called,holoprosencephaly (HPE). ... the most,common developmental malformation of the anterior ...
... Million in 2Q08 -- ... Million -- -- 2Q08 ... NEW YORK, Aug. 11 /Xinhua-PRNewswire-FirstCall/ -- American Oriental,Bioengineering, Inc. (NYSE: ... the development, manufacture and commercialization,of a broad range of prescription ...
... Tip and Other Consumables Revenue Up 15% Year over Year ... Gross Profit Margin of ... a leader in non-invasive tissue tightening in the aesthetic,industry, today reported its ... the second quarter of 2008 totaled $17.9 million, an,increase of 2% from ...
... provide context for tumor formation, new treatments ... about normal cells that give rise to cancer may ... to Duke University Medical Center researchers who identified cells ... the specific, normal cells that cancer come from can ...
... study finds , , MONDAY, Aug. 11 (HealthDay News) ... have the 20/20 vision physicians consider optimal because ... corneal curve known as astigmatism, a large, new ... common eye-focus problems -- collectively known as "refractive ...
... longer and with fewer disabilities, study finds , , MONDAY, Aug. ... to outrun death -- and even the creeping ravages of ... two decades has found that older runners live longer and ... findings probably apply to a variety of aerobic exercises, including ...
Cached Medicine News:Health News:New Insight Into Most Common Forebrain Malformation 2Health News:New Insight Into Most Common Forebrain Malformation 3Health News:American Oriental Bioengineering Reports Second Quarter 2008 Financial Results 2Health News:American Oriental Bioengineering Reports Second Quarter 2008 Financial Results 3Health News:American Oriental Bioengineering Reports Second Quarter 2008 Financial Results 4Health News:American Oriental Bioengineering Reports Second Quarter 2008 Financial Results 5Health News:American Oriental Bioengineering Reports Second Quarter 2008 Financial Results 6Health News:American Oriental Bioengineering Reports Second Quarter 2008 Financial Results 7Health News:American Oriental Bioengineering Reports Second Quarter 2008 Financial Results 8Health News:Thermage Announces Second Quarter 2008 Financial Results 2Health News:Thermage Announces Second Quarter 2008 Financial Results 3Health News:Thermage Announces Second Quarter 2008 Financial Results 4Health News:Thermage Announces Second Quarter 2008 Financial Results 5Health News:Thermage Announces Second Quarter 2008 Financial Results 6Health News:Thermage Announces Second Quarter 2008 Financial Results 7Health News:Thermage Announces Second Quarter 2008 Financial Results 8Health News:Thermage Announces Second Quarter 2008 Financial Results 9Health News:Researchers Hunt Normal Cells That Give Rise to Cancer 2Health News:Half of U.S. Adults Lack 20/20 Vision 2Health News:Half of U.S. Adults Lack 20/20 Vision 3Health News:Run for Your Life 2Health News:Run for Your Life 3
Bacterial/Viral Filters for Anesthesia and Respiratory Applications...
Bacterial/Viral Filters for Anesthesia and Respiratory Applications...
Ballard trach care HMES and filters, universal use, "Y" filter, CO 2 sampling port...
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours...
Medicine Products: